Clinical trial

PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

NCT07128290

Study summary

ClinicalTrials.gov

PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention CISGEM + Rilvegostomig Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-10-30

PhasePHASE2

Conditions

Intrahepatic Cholangiocarcinoma (Icc)unresolved

Interventions

CISGEM + RilvegostomigDRUG

Sponsors & collaborators

Federation Francophone de Cancerologie Digestivelead sponsor

Mapped research locations

DijonFrance2 MarseilleFrance1 NantesFrance1 CaenFrance1 GrenobleFrance1 PoitiersFrance1 LimogesFrance1 NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07128290 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.